- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01255384
Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes
Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes: Molecular Studies of the Placenta and Cord Blood and Possible Correlation to Postnatal Development.
Pregestational diabetes (PGD) during pregnancy may be associated with an increased rate of spontaneous abortions, intrauterine death and congenital anomalies among the offspring. Although the prevalence of congenital anomalies among the offspring of diabetic mothers is reduced as a result of the improvement of the glycemic control in the early pregnancy, the rate of congenital anomalies is increased and there seems to be an increased rate of neurodevelopmental disorders including some fine and gross motor deficits as well as increased rate of inattention and/or hyperactivity. In gestational diabetes, that develops in the second half of pregnancy (past the period of major organogenesis), there seems to be no increase in the rate of major congenital anomalies but there are some developmental disorders in the offspring.
The exposure of the developing embryo and fetus to diabetic environment (i.e. hyperglycemia, hyperketonemia ext), is known to cause increased oxidative stress and significant changes in gene expression as observed in several experimental diabetic models. We hypothesize that diabetic environment may also cause long lasting epigenetic changes. It is therefore our purpose to evaluate these possible epigenetic changes and correlate their presence with the degree and time of onset of diabetes, (i.e. whether from the beginning as in PGD or in the second half of pregnancy as in GD), the degree of oxidative stress and with the neurodevelopmental outcome of the offspring. Diabetic pregnancies will be compared to a similar number of normal pregnancies in all parameters studied.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Asher Ornoy, MD
- Phone Number: 0097226758329
- Email: ornoy@cc.huji.ac.il
Study Contact Backup
- Name: Zivanit Ergaz Shaltiel, MD
- Phone Number: 00972507874285
- Email: zivanit@hadassah.org.il
Study Locations
-
-
-
Jerusalem, Israel
- Hadassah Medical Organization, Jerusalem, Israel
-
Sub-Investigator:
- Simcha Yagel, MD
-
Principal Investigator:
- Asher Ornoy, MD
-
Principal Investigator:
- Zivanit Ergaz shaltiel, MD
-
Sub-Investigator:
- Drorit Hochner, MD
-
Sub-Investigator:
- Uri Elchalal, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Infants born to women suffering from pre-gestational or gestational diabetes.
Exclusion Criteria:
- Non Jewish population
- Triplets and up
- Premature infants under 32 weeks
- Infants suffering from major congenital anomalies
- Infants with chromosomal aberrations
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Non Diabetic-Controls
Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
|
Diabetic Pregnancy
Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Asher Ornoi, MD, Hadassah Medical Organization
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPI-DIABETES-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany